amyloid beta peptide inhibitors I (Amgen)

N/A

Report date: 2025/03/18 20:00:05
NME

Base Information

Drug Nameamyloid beta peptide inhibitors I (Amgen)
Drug Alias NameAlzheimers therapy (Amgen)fenchylamine sulfonamides (Amgen)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBeta amyloid A4 protein inhibitorsBeta amyloid A4 protein aggregation inhibitors
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAmgen Inc
Active IndicationsN/A
Inactive IndicationsAlzheimer Disease

Other Information

ATC CodeN/A
Related LinksN/A